Structure–activity relationship (SAR) studies of 3-(2-amino-ethyl)-5-(4-ethoxy-benzylidene)-thiazolidine-2,4-dione: Development of potential substrate-specific ERK1/2 inhibitors
- 1 November 2009
- journal article
- research article
- Published by Elsevier BV in Bioorganic & Medicinal Chemistry Letters
- Vol. 19 (21), 6042-6046
- https://doi.org/10.1016/j.bmcl.2009.09.057
Abstract
No abstract availableKeywords
This publication has 28 references indexed in Scilit:
- Pharmacological Exploitation of the Peroxisome Proliferator-Activated Receptor γ Agonist Ciglitazone To Develop a Novel Class of Androgen Receptor-Ablative AgentsJournal of Medicinal Chemistry, 2008
- Differential regulation and properties of MAPKsOncogene, 2007
- Characterization of ATP-independent ERK inhibitors identified through in silico analysis of the active ERK2 structureBioorganic & Medicinal Chemistry Letters, 2006
- Simultaneous activation of multiple signal transduction pathways confers poor prognosis in acute myelogenous leukemiaBlood, 2006
- Docking Interactions Induce Exposure of Activation Loop in the MAP Kinase ERK2Structure, 2006
- Involvement of MEK–ERK signaling pathway in the inhibition of cell growth by troglitazone in human pancreatic cancer cellsBiochemical and Biophysical Research Communications, 2005
- Targeting RAS signalling pathways in cancer therapyNature Reviews Cancer, 2003
- Mutations of the BRAF gene in human cancerNature, 2002
- Troglitazone Suppresses Cell Growth of Myeloid Leukemia Cell Lines by Induction of p21WAF1/CIP1 Cyclin-Dependent Kinase InhibitorBiochemical and Biophysical Research Communications, 1999
- Development and validation of a genetic algorithm for flexible dockingJournal of Molecular Biology, 1997